Skip to main content
. 2024 Dec 20;22:1125. doi: 10.1186/s12967-024-05917-x

Fig. 3.

Fig. 3

Napabucasin-PLGA NPs downregulate p-STAT3Try705 levels and stemness characteristics of HCC cells. A Immunoblot showed STAT3 and p-STAT3Try705 levels in Huh7 cells treated with different concentrations of Napabucasin-PLGA NPs. B The mRNA levels of stemness markers in HCC cells treated with Napabucasin (1 μM) or Napabucasin-PLGA NPs (1 μM) for 12 h. C HCC cells were treated with different concentrations of Napabucasin or Napabucasin-PLGA NPs, and the colony formation was detected on day 15. D HCC cells were treated with Napabucasin or Napabucasin-PLGA NPs, and the sphericity was detected on day 10. Napa, Napabucasin; Napa NPs, Napabucasin-PLGA NPs. Data are shown as mean ± SD from three independent experiments. Compared with 0 μM, one-way ANOVA with Tukey test. *p < 0.05, **p < 0.01